FGF-23 and LVH in HD Patients
associated with mortality among patients undergoing HD. 7, 8 Given that a major target organ of FGF-23 is the kidney, the association between FGF-23 levels and clinical outcome in HD patients suggests that FGF-23 may play a role in conferring cardiovascular risk on HD patients, independent of its role in the renal reabsorption of inorganic phosphate.
Besides accelerated arterial calcification, left ventricular hypertrophy (LVH) is a common manifestation of cardiovascular disease and has an important prognostic value in patients with ESRD. 9 Recent data suggest that hyperphosphatemia per se induces LVH and that correction of hyperphosphatemia may reduce LVH via a reversible pathway. 10 Isolated hyperphosphatemia in an animal model of chronic renal failure induced LVM, although no vascular calcification was observed. 11 Several biomarkers, such as B-type natriuretic peptide (BNP), cardiac troponin T (cTnT), and C-reactive protein (CRP), are predictors of mortality in patient with HD, 12, 13 and play an important role in the assessment of cardiovascular risk because each reflects a distinct aspect of the cardiac status. In addition, echocardiographic measurements reflecting systolic and diastolic function can predict mortality of HD patients. 14 However, no study has examined the relationships among these biomarkers and FGF-23 in ESRD patients.
The present study was an attempt at understanding the role of FGF-23 in long-term HD patients by examining the associations between serum FGF-23 levels and other biomarkers, and echocardiographic parameters.
Methods

Study Population
All HD patients treated in Hidaka Rehabilitation Hospital in December 2007 were included in the study. All patients gave informed consent in accordance with the guidelines of the Human Clinical Study Committee of Hidaka Rehabilitation Hospital before participating in the study. We prospectively and consecutively enrolled patients with ESRD who had been on regular HD treatment, 3 times weekly on a 4-6-h schedule for at least 6 months. Data on demographic characteristics, medical history, medication (statins, angiotensinreceptor blockers, angiotensin-converting enzyme inhibitors, calcium channel-blockers, β-blockers, warfarin, activated vitamin D), and blood samples were collected in all subjects at the time of enrollment.
Blood Sampling and Laboratory Measurements
All laboratory measurements were performed before HD. Blood samples were collected without an anticoagulant and allowed to clot for at least 30 min, then centrifuged at 1,000 g (5,000 cycles/min) and 4°C for 10 min. The resulting supernatant was divided into aliquots that were stored at −70°C. Serum calcium, phosphate, cholesterol, and triglyceride levels were measured by routine automated laboratory procedures. Serum FGF-23 was measured with a sandwich enzyme-linked immunosorbent assay that uses a pair of monoclonal antibodies to measure biologically active fulllength FGF-23 (reference range: 10-50 pg/ml; Kainos Inc, Tokyo, Japan). Specificity of the antibodies used in this assay was determined by immunoprecipitation and western blotting. 15 For comparison, we also measured the iFGF-23 levels of 65 patients without renal dysfunction (mean age 68±11 years, creatinine 0.88±0.64). Serum cTnT levels were measured using the Elecsys cTnT assay (Elecsys Troponin T STAT Immunoassay, 3rd generation; Roche Diagnostics, Left ventricular (LV) mass was calculated according to the formula of Deveraux and indexed to body surface area. 17 Ejection fraction was calculated by the Teichholz method. 18 Fractional shortening was calculated by the formula: FS = (LVEDD -LVESD) / LVEDD × 100, where LVEDD and LVESD represent the diameter of the LV at end-diastole and end-systole, respectively. Left atrial volume (LAV) was calculated using the prolate-ellipsoid method. 19 Transmitral inflow was recorded using pulsed wave Doppler recordings at the mitral valve leaflet tips in the apical 4-chamber view. Peak velocities of early filling (E) and atrial filling (A), the E/A ratio and the deceleration time of the E wave were measured. Doppler tissue velocities were acquired at the septal mitral annulus. Peak systolic, early diastolic (e') and late diastolic (a') velocities were determined. All measurements were made by the same examiner under blind conditions.
Statistical Analysis
Baseline characteristics were assessed with standard descriptive statistics and all descriptive data are expressed as mean ± SD. The associations between FGF-23 levels and baseline demographic, clinical and laboratory variables and echocardiographic parameters were assessed by the determination of the Pearson product-moment correlation coefficient. Linear regression was used to examine the association between LVMI and baseline demographic, clinical, and laboratory variables. We used multivariable models to examine the relationship between LVMI and FGF-23 levels, adjusting for age, sex, dialysis duration, body mass index (BMI), serum calcium and phosphate concentrations and known prognostic biomarkers (BNP, cTnT, hs-CRP). We also used multivariable models to evaluate whether serum calcium, phosphate or biomarker is associated with LVMI, adjusting for age, sex, dialysis duration, BMI and FGF-23. All analyses were conducted using statistical software (SPSS, version 17.0.0, SPSS Japan Inc, Tokyo, Japan) and P-values less than 0.05 were considered to be statistically significant.
Results
Study Population
A total of 89 HD patients were studied: 2 patients were excluded because of poor echocardiographic images ( Table 1) . Mean dialysis duration was 5.8±5.0 years, confirming the majority of patients recruited for this study were on long-term, regular HD treatment, consistent with the study design. Chronic glomerular nephritis (n=43, 49%) and diabetic nephropathy (n=40, 46%) were major causes of HD among this population.
In the laboratory analysis, the serum FGF-23 levels in 87 dialysis patients were significantly higher than those of the healthy volunteers (1,171±553 vs 48±16 pg/ml, P<0.001) (Figure 1) . Mean serum cTnT levels were 0.063 ng/ml and this value was less than the decision cut point (>0.1 ng/ml) Figure 1 . Comparison of serum fibroblast growth factor-23 levels in healthy subjects (n=65) and hemodialysis patients (n=87). The boxes define the interquartile range with the median indicated by the cross bar. FGF-23 and LVH in HD Patients that has been generally accepted as reference value in the numerous previous studies. 20 Mean serum BNP levels were 562 pg/ml, and this value was 31.2-fold above the reference range (<18 pg/ml), but compared with patients with ESRD in other studies, this value may not indicate the very high risk population because BNP >700 pg/ml was significantly associated with cardiac mortality in HD patients. 12 We performed echocardiographic analysis of 87 patients. Cardiac systolic function as assessed by ejection fraction (EF) (61.5±9.6%) and left ventricular volumes (end-diastolic volume 110±35 ml, end-systolic volume 44±25 ml) were within normal value, and mean LVMI (150±39 g/m 2 ) was significantly higher than the reference values (men/women: 76±16/70±14 g/m 2 ) determined from 700 healthy Japanese. 21 In addition, the early diastolic mitral annuls e' velocity (4.1±1.4 cm/s) and transmitral E velocity (60.9±19.8 cm/s), and the ratio of mitral velocity to early diastolic velocity of the mitral annulus (E/e'; 16.0±7.0), which is a Doppler measurement of LV filling pressure, indicated impaired diastolic function with a slightly elevated LV end-diastolic pressure.
Relationships Among FGF-23 Level, Biomarkers and Echocardiographic Data
Among the biomarkers examined, univariate linear regression showed that serum phosphate (r=0.443, P<0.001), calcium (r=0.256, P=0.040) and hs-CRP levels (r=0.225, P=0.071), but not cTnT (r=−0.009, P=0.945) and BNP levels (r=−0.042, P=0.742), were significantly associated with FGF-23 levels ( Table 2 ). In addition, only LV mass index (LVMI) among all the echocardiographic data determined was significantly correlated with FGF-23 levels (r=0.268, P=0.039) (Figure 2) . Furthermore, FGF-23 levels were also associated with calcium-phosphate product (r=0.457, P<0.001), and the changes in phosphate levels before and after HD (r=0.309, P=0.013) ( Table 2) . In multivariable regression analysis that included all the aforementioned parameters, serum phosphate (β=0.419, P=0.001, confidence interval (CI) 57.12-207.7), Figure 2 . Regression of LVMI against serum fibroblast growth factor-23 levels (r=0.268, P=0.039). Table 4) . In multivariable regression analysis that included all the parameters examined in Table 3 , BNP (β=0.628, P=0.007, CI 0.011-0.067) and FGF-23 (β=0.316, P=0.031, CI 0.002-0.041) were independent correlates with LVMI ( Table 5) .
Discussion
To the best of our knowledge, this is the first study to investigate the relationship between serum FGF-23 levels and cardiac and inflammatory biomarkers that have been proven to be useful in stratifying cardiovascular risk, and between FGF-23 and echocardiographic measurements in dialysis patients without cardiac symptoms. The present study provides 3 major findings. First, we found that elevated serum FGF-23 levels were significantly correlated with LVMI, serum phosphate, serum calcium level and calcium-phosphate product, but not with BNP and cTnT levels. Second, FGF-23 was sig- CI, confidence interval. Other abbreviations as in Table 1 . Abbreviations as in Tables 1,3 .
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nificantly associated with LVMI, irrespective of serum phosphate and calcium levels. Finally, FGF-23, as well as BNP, but not cTnT, was independently associated with LVMI.
Association Between FGF-23 and LVH
It has been consistently shown that LVH is a powerful predictor for future cardiovascular outcomes, such as congestive heart failure, cardiac ischemia and arrhythmias, and stroke, in dialysis patients. 4, 22 Gutiérrez et al have recently reported that FGF-23 is associated with LVMI in asymptomatic patients with chronic kidney disease (CKD). 23 Unlike our study, the recruited subjects in that study were CKD
patients not yet requiring HD. Thus, the link between elevated FGF-23 levels and LVMI appears to be consistent in patients with CKD from moderate stage to end stage. Our finding that FGF-23 levels were associated with LVMI provides the clue to understand the pathogenesis of cardiovascular disease in uremic patients. Recently, Gutiérrez et al demonstrated that elevated FGF-23 concentrations at the initiation of HD are independently associated with increased 1-year mortality in a prospective cohort of 10,055 patients. 7 Importantly, a strong linear dose-response relationship was observed between FGF-23 levels and mortality, even after multivariable adjustment including serum phosphate, calcium, log parathyroid hormone and other confounders recorded in a clinical data base. In addition, FGF-23 levels were most informative when serum phosphate were relatively normal, thus FGF-23 could represent the novel risk biomarker for death in HD patients. Jean et al have recently reported similar findings in long-term HD patients. 8 However, the mechanistic link between elevated FGF-23 levels and increased mortality remains to be answered. Our present study suggests that patients with increased FGF-23 levels are likely to have LVH, which is the established principal risk factor driving the high rate of cardiovascular mortality in HD patients, and which may be reduced by L-carnitine supplementation. 24 In addition, we should emphasize that FGF-23 levels were associated with LVMI, irrespective of serum phosphate in our study. This finding is also consistent with the report by Gutierrez et al and Jean et al, who showed that an increased mortality in patients with elevated levels of FGF-23 was independent of serum phosphate levels. 7,8
FGF-23 as Novel Biomarker of Cardiovascular Remodeling
Numerous studies have reported that BNP and NT-pro-BNP are invariably elevated in HD patients and their levels increase with increasing severity of LVH, LV systolic dysfunction and diastolic dysfunction in HD patients. 25 Likewise, there is increasing evidence that the degree of cTnT elevation in asymptomatic HD patients strongly correlates with the severity of coronary atherosclerosis and LVH. 13, 26 Here, we showed that FGF-23 levels as well as BNP and cTnT levels were positively associated with LVMI in univariate analysis, whereas neither BNP nor cTnT levels were correlated with FGF-23 levels. These results suggest that FGF-23 appears to measure different aspect of LV overload from that evaluated by either cTnT or BNP.
Several mechanisms underlying the elevation of BNP, NT-pro-BNP and cTnT levels among HD patients have been proposed. They include increased LV wall stress, myocardial wall stretch, relative ischemic stress, silent ischemic injury and an apoptotic process in the setting of LVH or during the repetitive cardiac stresses provoked by dialysis. 27 Unlike BNP and cTnT, FGF-23 is a hormone synthesized and secreted by bone, and a major stimuli of FGF-23 secretion is an increased dietary phosphate intake. 6,28 Thus, we assume that FGF-23 is likely to correlate with LVH that is induced directly by hyperphosphatemia or indirectly via hyperphosphatemia-induced vascular calcification, which induces diastolic dysfunction in patients with chronic HD. 29 Further study is necessary to test these possibilities. In addition, a study to investigate whether the combination of the FGF-23 and BNP improves the prediction of mortality compared with FGF-23 alone is warranted.
FGF-23 and Mineral Homeostasis
Numerous studies indicate that disturbances in serum phosphate, calcium and calcium-phosphate product are associated with increased risk for cardiovascular morbidity and mortality in HD patients. 30 Our data showed that serum FGF-23 levels positively correlated with serum phosphate and calcium levels, calcium-phosphate product and changes in serum phosphate level before and after HD. These data confirm that serum phosphate is 1 of the main regulators of FGF-23 levels in uremic patients on maintenance HD, 31 and suggest that production of FGF-23 in the bone is continuously stimulated by phosphate load, whereas the normal negative feedback loop is no longer active with respect to FGF-23. These mechanisms may account for the markedly increased serum FGF-23 levels in uremic patients.
In this study, we measured FGF-23 and other biomarkers in blood samples withdrawn from patients before their HD sessions. In a separate study, we found that serum FGF-23 levels were higher in the post-dialysis samples compared with those from the pre-dialysis session (data not shown). The magnitude of the increase in FGF-23 level was comparable with that in the total cholesterol, LDL-C and HDL-C levels, suggesting that an increase FGF-23 after HD may be because of a decrease in circulating plasma volume.
It is interesting to note that serum FGF-23 levels were positively associated with serum calcium levels, which is consistent with the report by Jean et al, who showed that the highest FGF-23 quartile was associated with calcemia. 8 However, no correlation has been observed in patients who are beginning HD treatment. 7 We did not vigorously explore the precise mechanisms underlying the positive relationship between serum FGF-23 and serum calcium, but it is unlikely that such an association is related to the use of activated vitamin D, because the differences in serum FGF-23, calcium and 1,25(OH)2D levels between users and non-users of active vitamin D were not significant. In addition, no correlation was observed between FGF-23 and 1,25(OH)2D levels in our study patients. Thus, we excluded the possibility that use of activated vitamin D confounded our observation. Further studies will be required to understand the mechanism of the association between FGF-23 and calcium in HD patients.
Study Limitations
First, the patients in this study were enrolled in a single center and thus a selection bias could have been introduced. Second, the sample size was relatively small. Third, because we used the prolate-ellipsoid method for LAV analysis, the volumes may have been underestimated. 19 However, there is a significant correlation among the prolate-ellipsoid, biplane area-length and biplane Simpson's methods. If there was a significant association between FGF-23 levels and LAV, it should be detected. Finally, given that these results are crosssectional, we cannot draw definitive inferences on their direction or causality. Nevertheless, this is the first report to demonstrate a link between FGF-23 with LVMI and LVH in NEGISHI K et al.
long-term HD patients, and suggest the pathophysiology of the association between FGF-23 elevation and increased mortality that has been reported.
In addition, we performed echocardiography after HD, and thus mean LA pressure and LV end-diastolic pressure are likely to be lower than before HD. Given that LV diastolic function rather than LVMI is influenced by preload, 32 this may explain the difference in the correlation between LVMI and LV diastolic function; the correlation between LVMI and E/A ratio (r=−0.230, P=0.050) and between LVMI and the E/e' ratio (r=0.226, P=0.064) did not reach statistical significance, although there was a tendency. Furthermore, we should emphasize that there are potential limitations to LVMI measurement using the formula of Deveraux, because echocardiographic measurement of LV mass relies upon geometric assumptions derived from normal hearts and tends to overestimate the volume, although the measurement still correlates well with LVMI by magnetic resonance imaging. This warrants 3-dimensional echocardiographic measurement of LVMI in HD patients in the future.
Conclusions
Besides BNP, we have identified FGF-23 as a factor that is significantly associated with LVMI. FGF-23 could be a novel biomarker of LV overload, which is closely associated with the increased risk of death in HD patients.
